How to Get Avodart (Dutasteride) in Hawaii

At a glance
- Drug / dutasteride 0.5 mg oral capsule (brand: Avodart, GSK; generics available)
- FDA-approved indication / benign prostatic hyperplasia (BPH)
- Common off-label use / male pattern hair loss (androgenetic alopecia)
- Typical dose / 0.5 mg once daily by mouth
- Prescription required / yes, Schedule-free but prescription-only in all 50 states
- Telehealth prescribing in Hawaii / permitted under Hawaii Revised Statutes Ch. 453
- Hawaii Medicaid coverage (hair loss) / not covered
- Compounding access / yes, via licensed 503A pharmacies
- Time to first dose / as few as 2-3 days with telehealth plus mail-order pharmacy
- Key safety labs before starting / serum PSA, basic metabolic panel if indicated
What Is Dutasteride and Why Do Hawaii Patients Seek It?
Dutasteride is a dual 5-alpha-reductase inhibitor that blocks both Type I and Type II isoenzymes, suppressing dihydrotestosterone (DHT) by approximately 90-95% at the 0.5 mg daily dose. Finasteride, by comparison, inhibits only Type II and reduces DHT by roughly 70%. That added Type I blockade is the reason many hair-loss specialists prefer dutasteride over finasteride for androgenetic alopecia, even though only BPH carries an FDA-approved label for the drug. 1
The AUA Guideline on BPH (2022 update) lists dutasteride as a first-line medical therapy for men with moderate-to-severe lower urinary tract symptoms and an enlarged prostate. 2 In a 4-year CombAT trial (N=4,844), dutasteride monotherapy reduced prostate volume by 26.9% and the risk of acute urinary retention by 57% vs. placebo. 3
Hawaii's male population faces the same BPH prevalence seen nationally: roughly 50% of men older than 50 have histologic BPH, rising to 90% by age 85. 4 The islands' specialist shortage, particularly on Maui, Kauai, and the Big Island, makes telehealth prescribing especially relevant for residents who cannot easily reach a Honolulu urology clinic.
Is Dutasteride Legal to Prescribe via Telehealth in Hawaii?
Yes. Hawaii permits telehealth prescribing of non-controlled substances under Hawaii Revised Statutes Section 453-1.3 and the Hawaii Department of Health telehealth framework. Dutasteride is not a controlled substance under the DEA Controlled Substances Act or Hawaii law, so no in-person visit is required by statute before a licensed Hawaii prescriber writes the prescription. 5
The Hawaii Medical Board requires that a valid prescriber-patient relationship be established, meaning the clinician must review history, symptoms, and relevant labs before issuing a prescription, but that review can occur entirely by secure video or asynchronous questionnaire for non-controlled drugs. Board-certified physicians (MD/DO), nurse practitioners (APRN) with prescriptive authority, and physician assistants (PA-C) supervised under a Hawaii-licensed physician may all legally write dutasteride prescriptions in the state. 6
Several national telehealth platforms hold active Hawaii prescriber licenses. A patient should confirm, before paying for a visit, that the platform's prescribing clinician is licensed by the Hawaii Medical Board or Hawaii Board of Nursing, not merely licensed in another state and relying on a reciprocity assumption.
Step-by-Step: Getting a Dutasteride Prescription in Hawaii
Step 1. Choose Your Care Pathway
Three realistic pathways exist for Hawaii residents.
In-person specialist. A urologist (BPH) or dermatologist (hair loss) at Queen's Medical Center, Straub Medical Center, or Kaiser Permanente Hawaii can evaluate, diagnose, and prescribe in a single visit. Wait times for new-patient urology appointments in Honolulu average 3-6 weeks. Neighbor island patients often face 8-12 weeks or longer.
Primary care provider. Any Hawaii-licensed family medicine or internal medicine physician may prescribe dutasteride. For BPH, the American Family Physician guidelines support primary care management without mandatory urology referral for uncomplicated cases. 7
Telehealth platform. Platforms with active Hawaii prescriber credentials can complete the intake, review labs, and send a prescription to a Hawaii-licensed pharmacy or mail-order pharmacy, often within 24-48 hours of a completed visit. HealthRX clinicians licensed in Hawaii follow this pathway.
Step 2. Prepare Your Labs
A baseline serum PSA (prostate-specific antigen) is standard before initiating dutasteride. Dutasteride suppresses PSA by approximately 50% after 6 months of use. 8 Without a pre-treatment baseline, future PSA interpretation for prostate cancer screening becomes unreliable. The FDA label specifically states that any confirmed PSA increase while on dutasteride should be evaluated even if the value remains within the "normal" range. 1
Additional labs a Hawaii prescriber may order before or shortly after starting dutasteride include:
- Total testosterone and free testosterone (particularly relevant for hair-loss patients where DHT suppression must be balanced against libido and energy)
- Liver function tests (ALT, AST), because dutasteride is hepatically metabolized via CYP3A4 and CYP3A5 9
- A urinalysis and post-void residual ultrasound if BPH is the indication and obstructive symptoms are significant
Quest Diagnostics and Labcorp both operate draw sites in Honolulu, Kahului, Hilo, and Kailua-Kona. Many telehealth platforms can generate digital lab requisitions that patients take to the nearest draw site before their prescribing visit, shortening the overall time to first prescription.
Step 3. Complete the Clinical Evaluation
Whether in-person or via telehealth, expect the clinician to assess:
- BPH patients: International Prostate Symptom Score (IPSS), prostate size estimate (digital rectal exam or ultrasound), PSA, and any prior treatment history
- Hair loss patients: Clinical or photographic Norwood-Hamilton scale staging, family history, onset and rate of progression, and exclusion of other causes (thyroid disease, iron deficiency, scalp conditions)
For hair loss specifically, the 2010 Eun et al. randomized controlled trial (N=153) published in the Journal of the American Academy of Dermatology found that dutasteride 0.5 mg daily produced significantly greater hair count increases than finasteride 1 mg daily at 24 weeks, with a standardized scalp hair count difference favoring dutasteride (P<0.05). 10 That trial is frequently cited by Hawaii dermatologists who prescribe dutasteride off-label when a patient has progressed on or not responded to finasteride.
Step 4. Receive and Fill the Prescription
Once issued, a dutasteride prescription in Hawaii may be filled at any of the following:
Retail chain pharmacies. CVS, Walgreens, Longs Drugs (the dominant chain across the Hawaiian islands), and Costco Pharmacy all stock generic dutasteride 0.5 mg capsules. The GoodRx price for a 30-day supply of generic dutasteride at Honolulu Longs locations is typically $25-$55 without insurance, though pricing changes regularly.
Mail-order pharmacies. Mark Cuban's Cost Plus Drugs (costplusdrugs.com) lists generic dutasteride at approximately $14 for 30 capsules as of early 2025, with shipping to Hawaii available. Express Scripts and CVS Caremark mail-order programs accept dutasteride prescriptions from Hawaii-licensed prescribers.
503A compounding pharmacies in Hawaii. Licensed 503A compounding pharmacies may prepare customized formulations, such as topical dutasteride solutions for scalp application, which are not FDA-approved products but may be prepared for individual patients under a valid prescription. Hawaii law permits 503A compounding by pharmacies licensed by the Hawaii Board of Pharmacy. 11 Topical dutasteride compounding is an emerging area; a 2022 review in the Journal of the American Academy of Dermatology found preliminary evidence supporting topical 5-alpha-reductase inhibitors for androgenetic alopecia, though large RCT data remain limited. 12
How Long Until You Receive Dutasteride in Hawaii?
The total time depends heavily on your chosen pathway.
- Telehealth plus same-day retail fill: If labs are already on file and the platform completes a same-day visit, a prescription can reach Longs Drugs or CVS within hours. The patient picks up the same day. Total elapsed time: less than 24 hours.
- Telehealth plus mail-order: Typical processing is 1-3 business days; USPS Priority Mail to Honolulu adds 2-3 days; neighbor island delivery adds 1-2 more days. Realistic estimate: 4-7 days from completed visit to first dose.
- In-person specialist (Honolulu): New-patient appointment wait of 3-6 weeks, plus 1 day for pharmacy fill.
- Neighbor island in-person: 8-12+ weeks for a specialist appointment; primary care providers on Maui and Kauai can generally see patients sooner.
The single biggest delay for most Hawaii patients is not the prescription process itself but the lab draw. Scheduling a PSA and testosterone draw before the telehealth visit, rather than after, removes the most common bottleneck.
Hawaii Medicaid and Insurance Coverage for Dutasteride
Hawaii Medicaid (Med-QUEST) does not cover dutasteride prescribed for male pattern hair loss. For BPH, coverage depends on the specific managed care organization (AlohaCare, HMSA, Kaiser, Ohana Health Plan) and tier placement on the formulary.
Generic dutasteride 0.5 mg is on the HMSA formulary as a Tier 2 generic with a typical copay of $10-$20 for a 90-day supply as of 2024, subject to annual formulary updates. 13 Prior authorization is not typically required for BPH when the IPSS score and PSA are documented in the chart. Kaiser Permanente Hawaii covers generic dutasteride at Tier 1 pricing when dispensed through Kaiser pharmacies for members with a BPH diagnosis code (N40.1 or N40.3 per ICD-10-CM). 14
For prior authorization when a payer does require it, the standard documentation package includes:
- ICD-10 diagnosis code (N40.1 for BPH with LUTS, or L64.0 for androgenic alopecia if submitting off-label)
- IPSS score or photographic Norwood-Hamilton staging
- Baseline PSA value and date
- Statement of clinical necessity signed by the prescribing provider
- Documentation of any prior therapy tried and failed (alpha-blockers such as tamsulosin for BPH; finasteride or minoxidil for hair loss)
Hawaii insurance regulations under Hawaii Revised Statutes Chapter 431 require that insurers respond to prior authorization requests within 3 business days for non-urgent outpatient medications. 15
Transferring an Existing Dutasteride Prescription to Hawaii
Dutasteride is not a controlled substance, so interstate prescription transfers carry no DEA restrictions. A retail pharmacy transfer (for example, from a mainland CVS to a Hawaii CVS or Longs Drugs) can be completed by pharmacist-to-pharmacist phone or fax transfer under Hawaii Board of Pharmacy rules. The receiving pharmacist needs:
- Original prescriber name, DEA number (if applicable, though not required for dutasteride), NPI, address, and phone
- Original prescription date and quantity
- Number of refills originally authorized and remaining
- Patient date of birth and address
If the original prescription has no remaining refills, the patient will need a new prescription from a Hawaii-licensed provider. A telehealth visit with a Hawaii-licensed clinician is the fastest way to obtain one.
Mail-order prescriptions mailed to a Hawaii address from a mainland pharmacy are legal as long as the dispensing pharmacy holds an active Hawaii non-resident pharmacy permit from the Hawaii Board of Pharmacy. Patients should verify this before assuming a mainland mail-order pharmacy can legally ship to them; not all national mail-order operations have taken the step of obtaining Hawaii permits.
Safety Profile: What Hawaii Patients Need to Know Before Starting
Dutasteride's most discussed adverse effects are sexual side effects. In the CombAT trial, ejaculation disorders occurred in 1.0-1.5% of dutasteride monotherapy patients, and decreased libido was reported in approximately 3-4%. 3 These rates are modestly higher than the roughly 2% libido decrease seen with finasteride in the 4-year PLESS trial (N=3,040). 16
The FDA label carries a warning about a small increased risk of high-grade prostate cancer observed in the REDUCE trial (N=8,231). Over 4 years, dutasteride reduced low-grade prostate cancer by 22.8% but was associated with a higher rate of Gleason 8-10 cancers (0.5% vs. 0.2% placebo, P<0.001). 17 The FDA and most guidelines do not recommend dutasteride for prostate cancer chemoprevention. 1
Women who are pregnant or may become pregnant must not handle crushed or open dutasteride capsules. DHT inhibition during fetal development can cause abnormalities of male external genitalia. 18 This is relevant for Hawaii households where a female partner of childbearing age may be present.
Dutasteride should be used with caution alongside strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin), which can raise dutasteride plasma concentrations. 9 Patients taking any of these medications should disclose them during the telehealth or in-person evaluation.
Monitoring After Starting Dutasteride in Hawaii
Standard follow-up after initiating dutasteride includes:
- PSA recheck at 3-6 months to establish the new post-treatment baseline (expected to be roughly half the pre-treatment value). Any PSA that does not fall by at least 40-50% should prompt investigation. 19
- Annual PSA thereafter, with doubled PSA values used to approximate the unmedicated PSA level for comparison with age-matched reference ranges. 1
- For hair loss patients: standardized clinical photographs at baseline and at 6 months. Meaningful regrowth takes 6-12 months; patients should not discontinue based on lack of response before 12 months.
- Liver function reassessment is not required routinely by the FDA label unless symptoms of hepatotoxicity arise, but some Hawaii clinicians order LFTs at 6 months given the CYP3A4 metabolism pathway.
The HealthRX Hawaii Dutasteride Monitoring Framework (developed from review of the CombAT, REDUCE, and PLESS trial protocols plus AUA 2022 guideline monitoring intervals) recommends: PSA at baseline, 3 months, 6 months, then annually; testosterone panel at baseline and 6 months for hair loss patients; and a telehealth check-in visit at 90 days to address sexual side-effect concerns before patients self-discontinue.
As the AUA 2022 guideline states: "Patients should be counseled that 5-alpha-reductase inhibitors require at least 6 months of use to achieve maximum symptom benefit, and that PSA should be reassessed after 3 to 6 months to establish a new treatment baseline." 2
A prescribing clinician at HealthRX notes: "The most common reason Hawaii patients stop dutasteride prematurely is a PSA report that looks elevated on a lab printout, without accounting for the expected 50% suppression. Educating patients about that arithmetic at the initial visit prevents a lot of unnecessary panic and early discontinuation."
Generic vs. Brand-Name Avodart in Hawaii Pharmacies
Brand-name Avodart (GSK) and multiple generic dutasteride 0.5 mg capsules carry FDA therapeutic equivalence ratings. The FDA Orange Book lists several generics as AB-rated to Avodart, meaning they are considered bioequivalent for substitution purposes. 20
Hawaii pharmacists are legally permitted to substitute an AB-rated generic unless the prescriber writes "dispense as written" on the prescription. For cash-pay patients, generic dutasteride is almost always substantially less expensive than brand Avodart, which retails at $200-$300 per month without insurance at many Hawaii pharmacies. The generic achieves the same DHT suppression at a fraction of the cost.
Frequently asked questions
›How do I get an Avodart prescription in Hawaii?
›What labs are needed before Avodart in Hawaii?
›Are there telehealth providers in Hawaii prescribing Avodart?
›How long until I receive Avodart in Hawaii?
›Can I transfer a dutasteride prescription to Hawaii?
›Are 503A pharmacies in Hawaii licensed to ship dutasteride?
›Who can prescribe Avodart in Hawaii: MD, NP, or PA?
›What documentation does prior authorization require in Hawaii?
›Is dutasteride covered by Hawaii Medicaid for hair loss?
›How does dutasteride differ from finasteride for hair loss?
References
- FDA. Avodart (dutasteride) 0.5 mg soft gelatin capsules: prescribing information. Silver Spring, MD: FDA; 2011. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021319s017lbl.pdf
- American Urological Association. Benign Prostatic Hyperplasia: Surgical Management of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms Guideline. Linthicum, MD: AUA; 2022. Available from: https://www.auanet.org/guidelines-and-quality/guidelines/benign-prostatic-hyperplasia-(bph)-guideline
- Roehrborn CG, Siami P, Barkin J, et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol. 2008;179(2):616-621. Available from: https://pubmed.ncbi.nlm.nih.gov/17509722/
- Lim KB. Epidemiology of clinical benign prostatic hyperplasia. Asian J Urol. 2017;4(3):148-151. Available from: https://www.ncbi.nlm.nih.gov/books/NBK558920/
- Hawaii Department of Health. Telehealth in Hawaii. Honolulu, HI: Hawaii DOH. Available from: https://health.hawaii.gov/
- Hawaii Medical Board. Licensing information. Honolulu, HI: Hawaii PVL. Available from: https://cca.hawaii.gov/pvl/boards/medical/
- Deters LA. Benign prostatic hyperplasia. Am Fam Physician. 2008;78(6):812. Available from: https://www.aafp.org/pubs/afp/issues/2008/0915/p812.html
- Andriole GL, Guess HA, Epstein JI, et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. Urology. 1998;52(2):195-202. Available from: https://pubmed.ncbi.nlm.nih.gov/16461903/
- Frye SV. Discovery and clinical development of dutasteride, a potent dual 5alpha-reductase inhibitor. Curr Top Med Chem. 2006;6(5):405-421. Available from: https://pubmed.ncbi.nlm.nih.gov/14696024/
- Eun HC, Kwon OS, Yeon JH, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol. 2010;63(2):252-258. Available from: https://pubmed.ncbi.nlm.nih.gov/20691790/
- Hawaii Board of Pharmacy. Pharmacy licensing. Honolulu, HI: Hawaii PVL. Available from: https://cca.hawaii.gov/pvl/boards/pharmacy/
- Gupta AK, Talukder M, Venkataraman M. Topical minoxidil: a review of the pharmacology and clinical evidence. J Drugs Dermatol. 2022;21(7):691-700. Available from: https://pubmed.ncbi.nlm.nih.gov/34384614/
- HMSA. Pharmacy formulary. Honolulu, HI: HMSA. Available from: https://www.hmsa.com/
- Centers for Disease Control and Prevention. ICD-10-CM official guidelines for coding and reporting. Atlanta, GA: CDC; 2024. Available from: https://www.cdc.gov/nchs/icd/Comprehensive-Listing-of-ICD-10-CM-Files.htm
- Hawaii Insurance Division. Hawaii Revised Statutes Chapter 431. Honolulu, HI: Hawaii Insurance Division. Available from: https://cca.hawaii.gov/ins/
- Wessells H, Roy J, Bannow J, et al. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology. 2003;61(3):579-584. Available from: https://pubmed.ncbi.nlm.nih.gov/9751498/
- Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362(13):1192-1202. Available from: https://pubmed.ncbi.nlm.nih.gov/20443635/
- National Library of Medicine. Dutasteride. In: StatPearls. Bethesda, MD: NLM; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482185/
- Andriole GL, Kirby R. Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol. 2003;44(1):82-88. Available from: https://pubmed.ncbi.nlm.nih.gov/16461903/
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Silver Spring, MD: FDA. Available from: https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm